In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Paratek Pharmaceuticals (PRTK), with a price target of $27. The company’s shares closed yesterday at $5.11, close to its 52-week low of $4.50.
Arce said:
“916-3963, Probability of success (POS) Risk-adj value Full value Rating NUZYRA – ABSSSI 100.0% $10.42 $10.42 Shares outstanding 32,416 S/O as of Apr 30, 2019.”
According to TipRanks.com, Arce is a 5-star analyst with an average return of 11.6% and a 41.6% success rate. Arce covers the Healthcare sector, focusing on stocks such as Madrigal Pharmaceuticals Inc, Arcturus Therapeutics Ltd, and Melinta Therapeutics Inc.
Paratek Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $21.75, a 325.6% upside from current levels. In a report released today, Ladenburg also maintained a Buy rating on the stock with a $18 price target.
See today’s analyst top recommended stocks >>
Based on Paratek Pharmaceuticals’ latest earnings release for the quarter ending December 31, the company reported a quarterly GAAP net loss of $22.79 million. In comparison, last year the company had a GAAP net loss of $27.75 million.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Paratek Pharmaceuticals, Inc. engages in the development and commercialization of therapies based upon tetracycline chemistry. Its products include omadacycline and sarecycline, which are used for the treatment of community-acquired bacterial infections, including community-acquired bacterial pneumonia, acute bacterial skin and skin structure infections and urinary tract infections. The company was founded by Walter Gilbert and Stuart B. Levy in 1996 and is headquartered in Boston, MA.
